Mersana Therapeutics Files 8-K on Operations
| Field | Detail |
|---|---|
| Company | Mersana Therapeutics, Inc. |
| Form Type | 8-K |
| Filed Date | Aug 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-condition, operations
TL;DR
Mersana Therapeutics filed an 8-K on Aug 13, 2025, updating on financials & operations.
AI Summary
Mersana Therapeutics, Inc. filed an 8-K on August 13, 2025, reporting on its results of operations and financial condition, and including financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text.
Why It Matters
This filing indicates Mersana Therapeutics is providing updates on its financial health and operational status to the SEC, which is crucial for investors to assess the company's performance.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of operational and financial information, not indicating any immediate adverse events.
Key Players & Entities
- Mersana Therapeutics, Inc. (company) — Registrant
- August 13, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 840 Memorial Drive Cambridge, Massachusetts 02139 (address) — Principal Executive Offices
FAQ
What specific financial results or operational updates are detailed in this 8-K filing?
The provided text of the 8-K filing indicates it pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits,' but it does not contain the specific details of these results or updates.
When was this Form 8-K filed with the SEC?
This Form 8-K was filed on August 13, 2025.
What is the principal executive office address for Mersana Therapeutics, Inc.?
The principal executive office address is 840 Memorial Drive, Cambridge, Massachusetts 02139.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is Mersana Therapeutics, Inc.'s state of incorporation?
Mersana Therapeutics, Inc. is incorporated in Delaware.
Filing Stats: 527 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2025-08-13 07:13:33
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value MRSN The Nasdaq Stock Marke
Filing Documents
- tm2523277d1_8k.htm (8-K) — 28KB
- tm2523277d1_ex99-1.htm (EX-99.1) — 51KB
- 0001104659-25-077187.txt ( ) — 248KB
- mrsn-20250813.xsd (EX-101.SCH) — 3KB
- mrsn-20250813_lab.xml (EX-101.LAB) — 33KB
- mrsn-20250813_pre.xml (EX-101.PRE) — 22KB
- tm2523277d1_8k_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 13, 2025, Mersana Therapeutics, Inc. (the "Company") issued a press release announcing business updates and financial results for the fiscal quarter ended June 30, 2025. The information furnished in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing by the Company with the Securities and Exchange Commission (the "SEC") under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, regardless of any general incorporation language contained in such filing, except as expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by the Company on August 13, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MERSANA THERAPEUTICS, INC. Date: August 13, 2025 By: /s/ Brian DeSchuytner Brian DeSchuytner Senior Vice President, Chief Operating Officer and Chief Financial Officer